Any current/future new fundraising through debt or equity?

For the current year, Hikal plans to complete ongoing capex with INR 200 crores, of which INR 100 crores is already completed. Some additional funding will be needed from the next quarter (H2 FY '24) to complete unfinished projects. There will be some debt funding in H2 FY '24, but this will be balanced by incoming equity. The company expects good profits in H2 FY '24, helping maintain debt-equity ratios around the current level (approximately 0.61). For the next year, capex will be slightly lower as efforts focus on utilizing existing assets, with no explicit mention of large new fundraising.

Any current/future capex/capital investment/strategic investment?

Current year capex planned is around INR 200 crores, with approximately INR 100 crores already completed. Next year's capex expected to be slightly lower, focusing on filling up existing assets rather than new expansions. Completion and commissioning of new facilities like the multipurpose Animal Health facility at Panoli are underway; full production ramp-up expected by March-April FY '25. Continuing investments in new plants, including Crop Protection assets, with commissioning starting soon. Asset capitalization occurs upon project completion, not at first commercial batch. Large

Future growth expectations in sales/revenue/volumes?

Volume growth for H1 FY24: Pharma volumes grew by 4%, Crop Protection volumes degrew by 26%, leading to overall 16% volume decline (Page 16). Crop Protection volume expected to improve starting Q4 FY24 with channel inventory normalization (Page 16). Sales growth targets: Management expects top line to grow substantially over the next 3-4 years with a target of INR 3,500-4,000 crores by FY26/FY27 (Page 10). New product launches and increased CDMO proportion in Pharma to support revenue growth (Pages 4, 11, 15). Capex completion and ramp-up expected by FY25 to drive incremental sales, wi

Future growth expectations in earnings/operating earnings/profits/EPS?

Pharma volumes grew 4% in H1 FY24; Crop Protection volumes degrew 26%, causing overall 16% decline. Signs of improvement in Crop Protection expected from Q4 FY24 as channel inventory normalizes. New product mix and CDMO business expected to improve margins significantly going forward. Capex commissioning for new plants anticipated by Q1/Q2 FY25, with ramp-up over 18-24 months. Revenue growth target of INR 3,500 to 4,000 crores by FY26-FY27 affirmed. Profitability and margins expected to improve sequentially in H2 FY24 due to cost optimization and better product mix. EBITDA margin expected to i

Current/ Expected Orderbook/ Pending Orders?

The earnings call transcript does not specify exact current orderbook or pending order values. Manoj Mehrotra highlighted increased customer inquiries and audits in the CDMO business, indicating a growing funnel of potential projects. Several new projects are under development due to increased new customer audits and exploration of new geographical markets. The Crop Protection business is at advanced stages of discussions with customers for new projects expected to yield positive medium- to long-term results. Validation batches for Animal Health products are planned over the next 4 to 6 quarte

HikalQ2 FY24Pharmaceuticals & Biotechnology

Hikal Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 63.3Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Volume growth for H1 FY24: Pharma volumes grew by 4%, Crop Protection volumes degrew by 26%, leading to overall 16% volume decline (Page 16).
Crop Protection volume expected to improve starting Q4 FY24 with channel inventory normalization (Page 16).
Sales growth targets: Management expects top line to grow substantially over the next 3-4 years with a target of INR 3,500-4,000 crores by FY26/FY27 (Page 10).
New product launches and increased CDMO proportion in Pharma to support revenue growth (Pages 4, 11, 15).
Capex completion and ramp-up expected by FY25 to drive incremental sales, with some ramp-up over 1-2 years post-commissioning (Pages 9-10).
Ongoing customer interest and inquiries from new geographies in both Pharma and Crop Protection segments underpin growth optimism (Pages 7, 11, 15).

Margin guidance

Category 1

Pharma volumes grew 4% in H1 FY24; Crop Protection volumes degrew 26%, causing overall 16% decline.
Signs of improvement in Crop Protection expected from Q4 FY24 as channel inventory normalizes.
New product mix and CDMO business expected to improve margins significantly going forward.
Capex commissioning for new plants anticipated by Q1/Q2 FY25, with ramp-up over 18-24 months.
Revenue growth target of INR 3,500 to 4,000 crores by FY26-FY27 affirmed.
Profitability and margins expected to improve sequentially in H2 FY24 due to cost optimization and better product mix.
EBITDA margin expected to increase 2-3% with CDMO ramp-up in H2 FY24.
Debt levels stable; future expansion capex may require moderate funding but equity infusion and profits expected to maintain debt-equity ratio.
ROE below cost of capital in Q2 FY24 seen as one-off; expected to recover with improved margins and volume growth.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

For the current year, Hikal plans to complete ongoing capex with INR 200 crores, of which INR 100 crores is already completed.
Some additional funding will be needed from the next quarter (H2 FY '24) to complete unfinished projects.
There will be some debt funding in H2 FY '24, but this will be balanced by incoming equity.
The company expects good profits in H2 FY '24, helping maintain debt-equity ratios around the current level (approximately 0.61).
For the next year, capex will be slightly lower as efforts focus on utilizing existing assets, with no explicit mention of large new fundraising.
Overall, internal cash flows are expected to cover most expansion capex, but some measured debt and equity raising is anticipated to complete existing projects.

Order book

The earnings call transcript does not specify exact current orderbook or pending order values.
Manoj Mehrotra highlighted increased customer inquiries and audits in the CDMO business, indicating a growing funnel of potential projects.
Several new projects are under development due to increased new customer audits and exploration of new geographical markets.
The Crop Protection business is at advanced stages of discussions with customers for new projects expected to yield positive medium- to long-term results.
Validation batches for Animal Health products are planned over the next 4 to 6 quarters, marking progress towards commercialization.
The company expects CDMO demand to revive and normalization towards Q4 FY '24, implying an increase in orderbook going forward.
Overall, the company is witnessing increased traction and new business inquiries across Pharma and Crop Protection segments, but no specific orderbacklog numbers were disclosed.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year capex planned is around INR 200 crores, with approximately INR 100 crores already completed.
Next year's capex expected to be slightly lower, focusing on filling up existing assets rather than new expansions.
Completion and commissioning of new facilities like the multipurpose Animal Health facility at Panoli are underway; full production ramp-up expected by March-April FY '25.
Continuing investments in new plants, including Crop Protection assets, with commissioning starting soon.
Asset capitalization occurs upon project completion, not at first commercial batch.
Large ongoing capex of approximately INR 500-550 crores over past years, with around INR 480-490 crores expected to be capitalized this year.
Additional funding may be required in H2 for incomplete projects, but internal cash flows and equity infusion will keep debt-equity ratio stable (~0.61).
Focus remains on technology, operational efficiency, and capacity ramp-up for medium to long-term growth.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHikal

Rev 3Mar 1

See where Hikal sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →